Imperial College London

ProfessorTimothyHallett

Faculty of MedicineSchool of Public Health

Professor of Global Health
 
 
 
//

Contact

 

+44 (0)20 7594 1150timothy.hallett

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Heffernan:2019:10.1016/S0140-6736(18)32277-3,
author = {Heffernan, A and Cooke, G and Nayagam, S and Hallett, TB and Thursz, M},
doi = {10.1016/S0140-6736(18)32277-3},
journal = {Lancet},
pages = {1319--1329},
title = {Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model},
url = {http://dx.doi.org/10.1016/S0140-6736(18)32277-3},
volume = {393},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BackgroundThe revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's elimination targets could be met.MethodsWe developed a dynamic transmission model of the global HCV epidemic, calibrated to 190 countries, which incorporates data on demography, people who inject drugs (PWID), current coverage of treatment and prevention programmes, natural history of the disease, HCV prevalence, and HCV-attributable mortality. We estimated the worldwide impact of scaling up interventions that reduce risk of transmission, improve access to treatment, and increase screening for HCV infection by considering six scenarios: no change made to existing levels of diagnosis or treatment; sequentially adding the following interventions: blood safety and infection control, PWID harm reduction, offering of DAAs at diagnosis, and outreach screening to increase the number diagnosed; and a scenario in which DAAs are not introduced (ie, treatment is only with pegylated interferon and oral ribavirin) to investigate the effect of DAA use. We explored the effect of varying the coverage or impact of these interventions in sensitivity analyses and also assessed the impact on the global epidemic of removing certain key countries from the package of interventions.FindingsBy 2030, interventions that reduce risk of transmission in the non-PWID population by 80% and increase coverage of harm reduction services to 40% of PWID could avert 14·1 million (95% credible interval 13·0–15·2) new infections. Offering DAAs at time of diagnosis in all countries could prevent 640000 deaths (620000–670000) from cirrhosis and liver cancer. A comprehensive p
AU - Heffernan,A
AU - Cooke,G
AU - Nayagam,S
AU - Hallett,TB
AU - Thursz,M
DO - 10.1016/S0140-6736(18)32277-3
EP - 1329
PY - 2019///
SN - 0140-6736
SP - 1319
TI - Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model
T2 - Lancet
UR - http://dx.doi.org/10.1016/S0140-6736(18)32277-3
UR - http://hdl.handle.net/10044/1/64741
VL - 393
ER -